skip to Main Content

Amelia Glynn

Tell us about yourself

My name is Amelia Glynn. I am a first year PME student in the University of Limerick. I have a love for science, and aspire to teach chemistry and biology upon graduating. Through this programme, I want to know the skills and mindset needed to work in an industry position. I would love to use my experiences to enrich my lessons and help develop those skills in my students. I also believe this programme will give me the confidence to show my students an accurate picture of what working in an industry position is really like, which would be impossible without real life experience.

I applied to the STInt Programme because...

This experience will hugely benefit me, as it will enable me to bring my perspective of working in an industry position to my students. I want to use moments from my firsthand experience to motivate my students and have the confidence to show them an accurate picture of what working in the STEM industry is like. I also want to learn as much as possible in this programme, like what skills are required of a person working in this industry, and create lessons that develop those skills in my students. I know this will positively impact my class content, and give my students real insight into the modern STEM industry.

STInt host

BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today. Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.  Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.

Amelia Glynn
Back To Top